Revenue: As of FY2025 Q1, the actual value is USD 65.7 M.

EPS: As of FY2025 Q1, the actual value is USD 0.01.

EBIT: As of FY2025 Q1, the actual value is USD 2.543 M.

Segment Revenue

• Total Revenue: $65.7 million, a 49% increase year-over-year.
• Telehealth Revenue: $52.5 million, a 70% increase year-over-year.
• WorkSimpli Revenue: $13.2 million, unchanged from the previous year.

Operational Metrics

• Net Income: $0.6 million, compared to a net loss of - $7.5 million in the previous year.
• Gross Margin: 87%, down from 90% due to revenue mix and the launch of LifeMD’s pharmacy.
• Adjusted EBITDA: $8.7 million, up from $0.1 million in the previous year.
• Telehealth Adjusted EBITDA: $5.3 million, compared to a loss of - $1.3 million in the previous year.

Cash Flow

• Cash: $34.4 million as of March 31, 2025.

Unique Metrics

• Telehealth Active Subscribers: Increased 22% to approximately 290,000.
• Total Active Subscribers: Increased 11% to 448,925.

Outlook / Guidance

• LifeMD raised its full-year 2025 guidance for total revenues to $268-$275 million and adjusted EBITDA to $31-$33 million, reflecting strong performance in telehealth.
• For the second quarter of 2025, expected total revenues are $65-$67 million, with telehealth revenue of $52-$53 million.